| Date | Title | Description |
| 01.11.2024 | CARsgen® U.S. Clinical Holds Lifted by FDA | SHANGHAI, Nov. 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S.... |
| 31.08.2024 | CARsgen Therapeutics: A New Dawn in CAR T-Cell Therapy | In the bustling landscape of biopharmaceuticals, CARsgen Therapeutics Holdings Limited stands out like a lighthouse in a storm. Based in Shanghai, this company is pioneering innovative CAR T-cell therapies aimed at tackling some of the most... |
| 29.08.2024 | CARsgen® Announces 2024 Interim Results | SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024... |
| 29.08.2024 | CARsgen® Announces 2024 Interim Results | SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced its 2024... |
| 27.08.2024 | CARsgen Therapeutics Corporation - 686504 - 07/26/2024 | Delivery Method: Via UPS and EMAIL Reference #: CBER 24-686504 Product: Biologics
Recipient:
Recipient Name
Zonghai Li, M.D.
Recipient Title
Chief Executive Officer CARsgen Therapeutics Corporation
4022 Stirrup Creek Drive
Durham, NC 27703
... |
| 19.08.2024 | CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel) | SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the com... |
| 15.06.2024 | CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024 | SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ini... |
| 04.06.2024 | CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO | SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the fina... |
| 04.06.2024 | CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO | SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the fina... |
| 29.04.2024 | CARsgen Submitted Responses to FDA Observations | SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that respon... |
| 27.03.2024 | CARsgen Announced 2023 Annual Results | SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, annou... |
| 01.03.2024 | NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma | SHANGHAI, March 1, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today t... |
| 19.01.2024 | CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting | SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the ... |
| 15.01.2024 | CARsgen's CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection | SHANGHAI, Jan. 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that CT011, ... |
| 12.12.2023 | CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting | SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the ... |
| 04.12.2023 | CARsgen's CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia | SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S.... |
| 20.11.2023 | CARsgen Announces Formation of its Clinical Advisory Board | SHANGHAI, Nov. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces the formatio... |
| 12.10.2023 | CARsgen's CAR-GPC3 T-cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-free Survival | SHANGHAI, Oct. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publicat... |
| 21.09.2023 | Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology | SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publica... |
| 22.08.2023 | CARsgen Announced 2023 Interim Results | SHANGHAI, Aug. 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Int... |
| 18.05.2023 | CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S. | SHANGHAI, May 18, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CARsgen ... |
| 05.05.2023 | CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer | SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in ... |
| 20.04.2023 | CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer | SHANGHAI, April 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CT041,... |
| 22.03.2023 | CARsgen Announced 2022 Annual Results and Business Updates | SHANGHAI, March 22, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2022 An... |
| 31.01.2023 | CARsgen Announces Collaboration Agreement to Evaluate AB011 in Combination with PD-L1 Checkpoint Inhibitor to Treat Gastric Cancer | SHANGHAI, Jan. 31, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative therapies for the treatment of hematologic malignancies and solid tumors, has announced CARsgen's execution... |
| 20.01.2023 | CARsgen Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI | SHANGHAI, Jan. 20, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a poste... |
| 16.01.2023 | CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China | SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, and Huadong Medicine (Hangzhou) Co... |
| 16.01.2023 | CARsgen Therapeutics and Huadong Medicine Announce Collaboration Agreement For Zevorcabtagene Autoleucel In Mainland China | SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, and Huadong Medicine (Hangzhou) Co... |
| 12.12.2022 | CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting | SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the ... |
| 18.10.2022 | CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA | SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Nat... |
| 24.08.2022 | CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline | SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, has announced the 2022... |
| 18.08.2022 | Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology | SHANGHAI, Aug. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that a case ... |
| 02.08.2022 | CARsgen Appoints Dr. Hua Jiang as Executive Director | SHANGHAI, Aug. 2, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua ... |
| 06.06.2022 | CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 | SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2... |
| 10.05.2022 | Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers | SHANGHAI, May 10, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phas... |
| 23.03.2022 | CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China | SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that ... |
| 23.03.2022 | CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies | SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 An... |
| 03.03.2022 | Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China | SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that t... |
| 17.01.2022 | CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation | SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors... |
| 20.09.2021 | Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO | SHANGHAI, Sept. 20, 2021 /PRNewswire/ -- On September 19, 2021, CARsgen Therapeutics (stock code: 2171.HK) disclosed the latest progress of the investigator-initiated trial (IIT) of Claudin18.2 (CLDN18.2) CAR-T (CT041) for the treatment of ... |
| 03.11.2020 | Carsgen Therapeutics lands $186M | Biotech startup Carsgen Therapeutics has raised a $186 million Series C led by private equity firm Loyal Valley Capital, with Lilly Asia Ventures, Shiyu Capital, Summer Capital and South China Venture Capital also participating. The Shangha... |
| 03.11.2020 | CARsgen Therapeutics Raises USD186M in Series C Equity Financing | CARsgen Therapeutics Holdings Limited, a Shangai, China-based biotechnology company focused on innovation and development of chimeric antigen receptor (CAR) T-cell therapeutics, raised a USD186m in Series C equity financing.
The round was l... |
| 02.11.2020 | Chinese biopharmaceutical firm CARsgen bags $186m Series C led by Loyal Valley | Clinical-stage immune-oncology therapy developer CARsgen Therapeutics Holdings Limited announced on Monday that it has secured $186 million in a Series C round financing led by Loyal Valley Capital.
The funding includes $30 million in full ... |
| 02.11.2020 | Chinese Biopharma firm CARsgen raises US$ 186M in Series C funding | - |
| 02.11.2020 | Chinese biopharmaceutical firm CARsgen bags $186m Series C led by Loyal Valley | Premium
Clinical-stage immune-oncology therapy developer CARsgen Therapeutics Holdings Limited announced on Monday that it has secured $186 million in a Series C round financing led by Loyal Valley Capital.
Continue reading this story with ... |
| 25.01.2016 | CARsgen Therapeutics Closes $30M Series B Financing | CARsgen Therapeutics, a Shanghai, China-based company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, completed a $30m Series B financing.
The round was led by KTB Ventures and Jolly Innovation Vent... |
| 25.01.2016 | Daily funding roundup - January 25, 2016 | CARSgen Therapeutics completed $30M funding; mPrest raised $20M; Wingz closed $11M Series B funding
DMWay Analytics, a Jerusalem, Israel-based startup specializing in expert systems for creating predictive analytics models, raised $1 millio... |